HELP     Sign In
Search

Relevance to Autism

According to a review (Dykens and Volkmar, 1997) of 14 studies, the percentages of individuals with Fragile X syndrome who met criteria for autism varied from 5 to 60%, with 7 studies finding more than 20%. As well, polymorphisms in the FMR1 gene have been found to be associated with autism. However, other studies have found no genetic association or only relatively rare identification of FMR1 with autism. Separately, several studies have found a CGG repeat polymorphism as well as rare variations in the FMR1 gene identified with Fragile X syndrome and general cognitive function.

Molecular Function

The protein encoded by this gene binds RNA and is associated with polysomes. The encoded protein may be involved in mRNA trafficking from the nucleus to the cytoplasm.

External Links

       

References

Type
Title
Type of Disorder
Associated Disorders
Author, Year
Primary
The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders.
Fragile X syndrome (FXS)
ASD, DD
Negative Association
Molecular and cytogenetic investigations of the fragile X region including the Frax A and Frax E CGG trinucleotide repeat sequences in families multiplex for autism and related phenotypes.
Autism
Negative Association
Association and transmission analysis of the FMR1 IVS10 + 14C-T variant in autism.
Autism
Support
Using whole-exome sequencing to identify inherited causes of autism.
ASD
Support
Point mutation analysis of the FMR-1 gene in autism.
Autism
Support
A point mutation in the FMR-1 gene associated with fragile X mental retardation.
MR
Support
Intragenic loss of function mutations demonstrate the primary role of FMR1 in fragile X syndrome.
MR
Highly Cited
Autism: the point of view from fragile X studies.
Fragile X
ASD
Highly Cited
The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein.
Recent Recommendation
Ca2+/calmodulin-dependent protein kinase IV links group I metabotropic glutamate receptors to fragile X mental retardation protein in cingulate cortex.
Recent Recommendation
A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model.
Recent Recommendation
Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP.
Recent Recommendation
Role of CTCF protein in regulating FMR1 locus transcription.
Recent Recommendation
Altered hippocampal synaptic plasticity in the FMR1 gene family knockout mouse models.
Recent Recommendation
Fragile X mental retardation protein controls gating of the sodium-activated potassium channel Slack.
Recent Recommendation
Enhanced asynchronous Ca(2+) oscillations associated with impaired glutamate transport in cortical astrocytes expressing Fmr1 gene premutation expansion.
Recent Recommendation
A novel function for fragile X mental retardation protein in translational activation.
Recent Recommendation
A functional requirement for PAK1 binding to the KH(2) domain of the fragile X protein-related FXR1.
Recent Recommendation
FMRP regulates neurotransmitter release and synaptic information transmission by modulating action potential duration via BK channels.
Recent Recommendation
Downregulation of tonic GABAergic inhibition in a mouse model of fragile X syndrome.
Recent Recommendation
Critical period plasticity is disrupted in the barrel cortex of FMR1 knockout mice.
Recent Recommendation
Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95.
Recent Recommendation
FMRP acts as a key messenger for dopamine modulation in the forebrain.
Recent Recommendation
Dysregulation of mTOR signaling in fragile X syndrome.
Recent Recommendation
FMRP targets distinct mRNA sequence elements to regulate protein expression.
Recent Recommendation
Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS).
Fragile X-associated tremor/ataxia syndrome
Recent Recommendation
Mouse model of fragile X syndrome: behavioral and hormonal response to stressors.
Recent recommendation
High-functioning autism spectrum disorder and fragile X syndrome: report of two affected sisters.
ASD
Recent Recommendation
mRNPs, polysomes or granules: FMRP in neuronal protein synthesis.

Rare

Variant ID
Variant Type
Allele Change
Residue Change
Inheritance Pattern
Inheritance Association
Family Type
Author, Year
 GEN093R001 
 Substitution 
 G138A 
 N/A 
  
  
  
 GEN093R002 
 Substitution 
 N/A 
 N/A 
  
  
  
 GEN093R003 
 Substitution 
 N/A 
 N/A 
  
  
  
 GEN093R004 
 Missense 
 T1100A 
 Ile304Asn 
 De novo 
  
  
 GEN093R005 
 Deletion 
 N/A 
 N/A 
 De novo 
  
  
 GEN093R006 
 Substitution 
 G23714TG23715A 
 N/A 
 Familial 
 Maternal 
  
 GEN093R007 
 Repeat 
 (CGG)450, 5'UTR 
  
 Familial 
 Maternal 
 Multiplex 
 GEN093R008 
 Repeat 
 (CGG)370, 5'UTR 
  
 Familial 
 Maternal 
 Multiplex 
 GEN093R009 
 Missense 
 c.1639A>G 
 K547E 
 Familial 
 Maternal 
 Simplex 

Common

No Common Variants Available



Model Summary

Fragile X Syndrome

External Links

AllenBrainAtlas   MGI Logo  Entrez Gene

References

Type
Title
Author, Year
Additional
Deletion of FMR1 in Purkinje cells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in Fragile X syndrome.
Additional
Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model.
Additional
The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo.
Additional
Major defects in neocortical GABAergic inhibitory circuits in mice lacking the fragile X mental retardation protein.
Additional
Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities.
Additional
Fragile X mental retardation protein is required for chemically-induced long-term potentiation of the hippocampus in adult mice.
Primary
Fmr1 knockout mice show reduced anxiety and alterations in neurogenesis that are specific to the ventral dentate gyrus.
Additional
Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.
Additional
Altered neuroligin expression is involved in social deficits in a mouse model of the fragile X syndrome.
Additional
A mouse model of the human Fragile X syndrome I304N mutation.
Additional
Dysregulation of mTOR signaling in fragile X syndrome.
Additional
GSK3 influences social preference and anxiety-related behaviors during social interaction in a mouse model of fragile X syndrome and autism.
Additional
A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis.
Additional
Hyperconnectivity and slow synapses during early development of medial prefrontal cortex in a mouse model for mental retardation and autism.
Additional
Reversal of fragile X phenotypes by manipulation of A?PP/A? levels in Fmr1KO mice.
Additional
The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.
Additional
Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X Syndrome.
Additional
Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice.
Additional
Activation of 5-HT7 serotonin receptors reverses metabotropic glutamate receptor-mediated synaptic plasticity in wild-type and Fmr1 knockout mice, a model of Fragile X syndrome.
Additional
Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice.
Additional
Reorganization of circuits underlying cerebellar modulation of prefrontal cortical dopamine in mouse models of autism spectrum disorder.
Additional
Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by the small-molecule PAK inhibitor FRAX486.
Additional
Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice.
Additional
Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model.
Primary
Pharmacological rescue of Ras signaling, GluA1-dependent synaptic plasticity, and learning deficits in a fragile X model.
Additional
Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.
Primary
Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring.
Additional
Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium.
Additional
Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits.

FMR1_1_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Fmr1 gene was generated by construction a targeting vector using homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin (neo).
Allele Type: Targeted (knock-out)
Strain of Origin:
Genetic Background: C57BL/6J
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: The Jackson Laboratory

FMR1_3_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: A germline null mutation was created by crossing Fmr1 mice, which has the first coding exon floxed, with mice that express Cre-recombinase in the germline (Tg(CAG-cre)13Miya). Gene inactivation was confirmed by a lack of protein expression in the brain and testes as determined by immunoblot analysis.
Allele Type: Targeted (knock-out)
Strain of Origin: C57BL/6J
Genetic Background: 129P2/OlaHsd * C57BL/6
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: Not Specified

FMR1_4_CN_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Conditional knock out mice by flaking the promoter and first exon of Fmr1 with bacteriophage P1-derived lox P sites
Allele Type: Conditional (knock-out)
Strain of Origin: C57BL/6J
Genetic Background: Not specified
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: Not Specified

FMR1_2_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Fmr1 gene was generated by construction a targeting vector using homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin (neo).
Allele Type: Targeted (knock-out)
Strain of Origin: C57BL/6J
Genetic Background: Not specified
ES Cell Line: E14
Mutant ES Cell Line: Not specified
Model Source: Not Specified

FMR1_6_I304N_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Homologous recombination mediated introduction of I304N mutation to Fmr1 locus
Allele Type: Targeted (Mutation)
Strain of Origin: Not Specified
Genetic Background: FVB x C57BL/6J
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

FMR1_5_KI_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Knock in of transgene containing ~120 CGG.CCG repeats in the Fmr1 gene with a Cre recombinase under the control of the MMTV promoter
Allele Type: Targeted (Knock In)
Strain of Origin: Not Specified
Genetic Background: C57BL/6
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

FMR1_7_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Homologous recombination against Exon 5 which was interrupted by the positive selection marker gene neomycin
Allele Type: Targeted (Knock Out)
Strain of Origin: Not Specified
Genetic Background: FVB
ES Cell Line: Not Specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

FMR1_8_KO_HM

Model Type: Genetic
Model Genotype: Homozygous
Mutation: Yeast artificial chromosome (YAC) transgenic mice overexpressing the human FMRP Protein
Allele Type: Targeted (Knock Out)
Strain of Origin: Not specified
Genetic Background: C57BL/6
ES Cell Line: Not specified
Mutant ES Cell Line: Not Specified
Model Source: Not Specified

Fmr1_1_KO_HM_5HT2bAG+D1AG+PI3K inhibitor

Model Type: Pharmaceutical intervention
Model Genotype: Homozygous
Mutation: Postnatal day 14 to 29 d old mice were anesthetized by an i.p. injection of 10mg/kg ketamine and 2mg/kg xylazine. A GluA1-GFP viral contruct was injected through a glass pipette, stereotaxically into the hippocampal CA1 region. For behavioral tests 10-12 injections of 6 ul high titer viral solutions were delivered along the entire hippocampus of both sides to achieve expression in one third of the CA1 pyramidal neurons. A cocktail of 5HT and Dopamine receptor agonist and antagonist was coadminis
Allele Type: Targeted (Knock out)
Strain of Origin: 129P2/OlaHsd
Genetic Background: C57BL/6
ES Cell Line:
Mutant ES Cell Line:
Model Source: JAX

Fmr1_1_KO_HM_GluA1CT-5HT2bAG+D1AG

Model Type: Pharmaceutical intervention
Model Genotype: Homozygous
Mutation: Postnatal day 14 to 29 d old mice were anesthetized by an i.p. injection of 10mg/kg ketamine and 2mg/kg xylazine. A GluA1ct-GFP viral contruct was injected through a glass pipette, stereotaxically into the hippocampal CA1 region. The GluA!ct is a GFP taged cytiplasmic domain of GluA1 receptor subunit that acts as a dominant negative construct selectively blocking synaptic trafficking of endogenous or viral GluA1 contianing AMPA-rs
Allele Type: Targeted (Knock out)
Strain of Origin: 129P2/OlaHsd
Genetic Background: C57BL/6
ES Cell Line:
Mutant ES Cell Line:
Model Source:

FMR1_1_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Size/Growth15
Increased
Description: Increased body weight
Exp Paradigm: General Observations
 General Observations
 2.5 - 6 months
Size/Growth2
Increased
Description: Increased testicular weight without structural differences at four different ages; Total weight and weight of kidney, heart, spleen, and liver were not statstically different
Exp Paradigm: General Observation; Light microscopic examination
 
 40-50; 60-70; 90-100; 160-170 days
Seizure10
Increased
Description: Increased incidence of audiogenic induced seizures (wild running, seizures, and death)
Exp Paradigm: Audiogenic seizure assay
 Audiogenic seizure assay
 21 days
Homeostasis5
Decreased
Description: Decreased corticosterone levels after acute stress
Exp Paradigm: Corticosterone Enzyme Immunoassay Kit on trunk blood serum after 3-h restraint procedure
 ELISA
 
EPSC Amplitude12
Decreased
Description: Decreased excitatory postsynaptic current amplitude after application of DHPG indicative of enhanced mGluR-LTD
Exp Paradigm: Whole cell recordings of hippocampal cultures
 Whole cell recordings
 PN0-PN1
EPSC Amplitude12
Increased
Description: Increased excitatory postsynaptic current amplitude after 8-OH-DPAT administration
Exp Paradigm: Whole cell recordings of hippocampal cultures
 Whole cell recordings
 PN0-PN1
Long Term Depression9
Decreased
Description: Decreased recovery of excitatory synaptic connections in pyramidal neurons
Exp Paradigm: Short-term depression of pyramidal neurons
 Short-term depression
 
Synaptic Connections9
Increased
Description: Increased unitary connectivity of neighboring pyramidal neurons
 
 
Synaptic Plasticity10
Increased
Description: increased mGluR-dependent Long Term Depression in hippocampus
Exp Paradigm: Field recordings in CA1 hippocampal slices
 Field recordings
 3 months
Brain Development5
Decreased
Description: Decreased neuronal cell survival in the ventral dentate gyrus
Exp Paradigm: BrdU immunohistochemical analysis
 Immunohistochemistry
 
Cytoarchitecture14
Abnormal
Description: Longer dendritic spines in Layer V pyramidal neurons from visual cortex
Exp Paradigm: Quantification using light microscope of sections fixed and mounted after being impregnated with Golgi-Cox
 
 16 weeks
Brain Morphology4
Decreased
Description: Decreased number of parvalbumin (PV) neurons in layers II/III and IV in somatosensory cortex
Exp Paradigm: Double immunohistochemistry and DAPI staining of the somatosensory cortex using anti-PV antibody
 Double immunohistochemistry
 PD365-380
Cytoarchitecture14
Abnormal
Description: Presence of both short and thin spines with the elongated spines being more present in higher density in Layer V pyramidal neurons
Exp Paradigm: Quantification using light microscope of sections fixed and mounted after being impregnated with Golgi-Cox
 
 16
Brain Morphology4
Increased
Description: Increased number of parvalbumin (PV) neurons in layers V and VI in somatosensory cortex
Exp Paradigm: Double immunohistochemistry and DAPI staining of the somatosensory cortex using anti-PV antibody
 Double immunohistochemistry
 PD365-380
Synapse Number15
Decreased
Description: Decreased numbers of excitatory synapses as indicated by puncta positive for PSD95 and Vglut
Exp Paradigm: Immunostaining analysis for PSD95 and Vglut
 Immunostaining Analysis
 2.5 - 6 months
Brain Cytoarchitecture4
Increased
Description: Increased soma area of parvalbumin (PV) neurons in thalamocortical slices
 Cell size measurement
 PD365-380
Cytoarchitecture14
Abnormal
Description: Abnormal Cytoarchitecture: Longer dendritic spines in Layer V pyramidal neurons from visual cortex
Exp Paradigm: Quantification using light microscope of sections fixed and mounted after being impregnated with Golgi-Cox
 Light Microscopic Analysis
 16 weeks
Synapse Number15
Increased
Description: Increased numbers of inhibitory synapses as indicated by puncta positive for gephyrin and VGAT
Exp Paradigm: Immunostaining analysis for gephyrin and VGAT
 Immunostaining Analysis
 2.5 - 6 months
Brain Cytonumber4
Decreased
Description: Decreaed number of Parvalbumin positive neurons in thalamocortical sections
Exp Paradigm: DAB staining of thalamocortical slices
 DAB staining
 PD365-380
Cytoarchitecture14
Abnormal
Description: Abnormal Cytoarchitecture: Presence of both short and thin spines with the elongated spines being more present in higher density in Layer V pyramidal neurons
Exp Paradigm: Quantification using light microscope of sections fixed and mounted after being impregnated with Golgi-Cox
 Light Microscopic Analysis
 16 Weeks
Differential gene expression3
Abnormal
Description: Abnormal Differential gene expression; 143 cDNAs underexpressed, 81 overexpressed
Exp Paradigm: Differential display technique of hippocampal tissue followed by identification of clones by comparing human and murine sequences from various databases
 Differential display technique of hippocampal tissue followed by identification of clones by comparing human and murine sequences from various databases
 9-13 weeks
Signaling1
Dereased
Description: There is decreased signal transduction between Ras GTP to PI3/PKB proteins in Fmr1 KO mice, as there is decreased phosphorylated PKB in the awake state in the KO mice, whereas there is increased phosphorylated PKB in WT mice in the awake state.
 Immunoblotting
 PND 14 or 29
GABAA receptor subunit gene expression3
Decreased
Description: Decreased expression of GABAA receptor subunit in neocortex and hippocampus. No change in cerebellum, caudate putamen, thalamus, and bulbus olfactorius
Exp Paradigm: Real-time PCR analysis of neocortex, cerebellum, hippocampus, caudate putamen, thalamus, bulbus olfactorius, and pons
 
 10 weeks
Amyloid Beta Protein Levels10
Increased
Description: Increased levels of Amyloid Beta and Amyloid beta precursor protein levels
Exp Paradigm: Western Blot analysis
 Western Blot analysis
 1 month
Protein modification1
Increased
Description: Fmr1 KO mice have elevated basal levels of Ras-GTP during sleeping and reduced ranges of Ras activation between sleeping and awake states comapred to WT mice. Both WT and Fmr1 KO mice had increased Ras-GTP in awake states
 Immunoblotting
 PND 14 or 29
Dopamine Release13
Decreased
Description: Decreased cerebellar evoked medial prefrontal cortex dopamine release
Exp Paradigm: Fixed potential amperometry in response to cerebellar electrical stimulation
 Fixed potential amperometry
 
TrkB protein expression4
Decreased
Description: Decreased TrkB protein expression as demonstrated by decreased number of puncta oriented perpendicularly to pia surface and reduction in total number of TrkB positive puncta
Exp Paradigm: Double immunohistochemistry of somatosensory cortex using antibodies against PV and TrkB
 Double immunohistochemistry
 PD365-380
Gene expression3
Abnormal
Description: Abnormal gene differential expression of 8 cDNAs
Exp Paradigm: Two-step real-time PCR and detection of intercalation of fluroscent SYBR green I from hippocampal tissue
 
 10-11 weeks
Basal levels and phosphorylation of GSK3 protein6
Decreased
Description: Decreased phosphorylation on inhibitory serines in the striatum, cerebral cortex, and hippocampus; No change in levels in cerebellum; No change in total levels of both isoforms of GSK4
Exp Paradigm: Immunoblot analysis of brain extracts using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 
 ~3 months
Serine-phosphorylation of GSK3 protein6
Increased
Description: Increase in both phospho-Ser9-GSK3 and phospho-Ser21-GSK3 after chronic treatment with lithium in striatum, hippocampus, cerebral cortex, and cerebellum
Exp Paradigm: Immunoblot analysis of brain extracts treated with 4mmole/kg of lithium, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 
 ~3 months
Dopamine Release13
Decreased
Description: Decreased mPFC dopamine release after intra-VTA lidocaine or kynurenate infusion
Exp Paradigm: Fixed potential amperometry in response to cerebellar electrical stimulation
 Fixed potential amperometry
 
TrkB protein expression4
Increased
Description: Increased expression of TrkB in cell bodies of parvalbumin expressing interneurons
Exp Paradigm: Double immunohistochemistry of somatosensory cortex using antibodies against PV and TrkB
 Double immunohistochemistry
 PD365-380
mTOR Kinase Activity7
Increased
Description: Increased mTOR Kinase activity demonstrated by increased association of mTOR with raptor in hippocampal slices
Exp Paradigm: Western Blot analysis and immunoprecipitation followed by immunoblotting with antibody against raptor of acute hippocampal slices
 Western Blot analysis and immunoprecipitation followed by immunoblotting
 4-6 weeks
BDNF Protein expression6
Increased
Description: Increased BDNF expression in hippocampal extracts after chronic lithium treatment
Exp Paradigm: ELISA
 
 ~3 months
Serine-phosphorylation of GSK3 protein6
Increased
Description: Increase in both phospho-Ser9-GSK3 and phospho-Ser21-GSK3 after treatment with lithium in striatum, hippocampus, cerebral cortex, and cerebellum at 30 minutes; Sustained increase after 90 minutes observed only in cerebellum
Exp Paradigm: Immunoblot analysis of brain extracts treated with 4mmole/kg of lithium, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 
 ~3 months
Dopamine Release13
Decreased
Description: Decreased mPFC dopamine release after intra=ThN v1 infusion of lidocaine or kynurenate
Exp Paradigm: Fixed potential amperometry in response to cerebellar electrical stimulation
 Fixed potential amperometry
 
mTOR Phosphorylation7
Increased
Description: Increased mTOR phosphorylation at Ser2448 in forebrain, whole cell lysates, and isolated postynaptic densities of hippocampus
Exp Paradigm: Western Blot analysis of lysates of hippocampus, cortex using p-mTOR antibodies
 Western Blot analysis
 4-6 weeks; 6-8 months
Differential gene expression3
Abnormal
Description: Abnormal Differential gene expression; 143 cDNA's underexpressed, 81 overexpressed
Exp Paradigm: Differential display technique of hippocampal tissue followed by identification of clones by comparing human and murine sequences from various databases
 
 9-13 weeks
Serine-phosphorylation of GSK3 protein6
Abnormal
Description: Increase in phospho-Ser21-GSK3 and phospho-Ser9-GSK3 after 30 min of MPEP treatment in the striatum, hippocampus, cerebral cortex, and cerebellum; Sustained increase in phospho-Ser9-GSK3 selectively in striatum after 90 min; No change in total level of GSK3 or GSK3
Exp Paradigm: Immunoblot analysis of brain extracts treated with 30mg/kg of MPEP, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 
 ~3 months
eIF4F Transcription Initiation Complex Formation7
Increased
Description: Increased phosophorylation of 4E-BP and association of eIF4G with eIF4E in hippocampal slices
Exp Paradigm: Immunoprecipitation with antibody to eIF4g followed by Western Blot with antibody to eIF4E of hippocampal slices
 Immunoprecipitation followed by Western Blot analysis
 4-6 weeks
Protein Expression15
Decreased
Description: Decreased expression of Nlgn1 in hippocampus and cerebellum, but not cortex
Exp Paradigm: Immunohistochemical analysis using anti-Nlgn1 antibodies
 Immunohistochemical analysis
 2.5 - 6 months
Social Interaction15
Decreased
Description: Decreased social interaction demonstrated by reduced active and passive contact time
Exp Paradigm: Direct social interaction task
 Direct social interaction task
 2.5 - 6 months
Social Interaction8
Decreased
Description: Decreased social interaction indicated by decreased duration of nose contacts with S1 mouse
Exp Paradigm: Quantification of duration of nose contacts with S1 stimulus mouse
 Social Interaction apparatus
 3 months
Sociability8
Increased
Description: Increased sociability demonstrated by increased time spent in Chamber 1
Exp Paradigm: Measurement of preference for chamber with an introduced mouse in social interaction apparatus after chronic lithium treatment
 Social Interaction apparatus
 3 months
Social preference8
Abnormal
Description: Abnormal social preference indicated by no significant preference for novel mouse compared to familiar mouse
Exp Paradigm: Comparison of interaction with familiar S1 mouse and novel S2 mouse
 Social Interaction apparatus
 3 months
Social Approach8
Increased
Description: Increased social approach evident by increased number of nose contacts with stimulus mouse
Exp Paradigm: Quantification of nose contacts with S1 stimulus mouse after chronic lithium treatment
 Social Interaction apparatus
 3 months
Social preference8
Increased
Description: Increased social preference indicated by social preference for S2 after treatment
Exp Paradigm: Comparison of interaction with familiar S1 mouse and novel S2 mouse after chronic lithium treatment
 Social Interaction apparatus
 3 months
Social Interaction15
Abnormal
Description: Abnormal decreased social interaction demonstrated by no significant preference for stimulus mouse
Exp Paradigm: Chambered social interaction paradigm; Resident-intruder paradigm
 Social Interaction paradigm; Resident-intruder paradigm
 2.5 - 6 months
Ultrasonic Vocalizations11
Decreased
Description: Decreased frequency of ultrasonic vocalizations (UsV)
Exp Paradigm: UsV produced during mating behavior
 UsV produced during mating behavior
 
Burying10
Decreased
Description: Decreased number of buried marbles
Exp Paradigm: Marble burying assay
 Marble burying assay
 8-10 weeks
Spontaneous Movement2
Increased
Description: Significantly more crossings in an empty cage
Exp Paradigm: Number of crossing through trhee infrared beams in an empty cage
 
 
Swimming15
Increased
Description: Increased swimming speed indicative of hyperactivity
Exp Paradigm: Swimming test
 Swimming test
 2.5 - 6 months
General Locomotor Activity15
Increased
Description: Increased general locomotor activity indicated by increased travel distance, travel speed, no. of line crossings, distance travelled in centre zone
Exp Paradigm: Open field test
 Open Field test
 2.5 - 6 months
Hyperactivity6
Increased
Description: Increased hyperactivity; Abolished by administration of lithium; Increased center-square behavior in open field; Reduced by administration of lithium
Exp Paradigm: Open field test
 
 ~3 months
Cued or contextual fear conditioning1
Decreased
Description: Fmr1 KO mice show significantly reduced freezing in the more demanding associative learning in trace fear conditioning paradigm comapred to WT controls
Exp Paradigm: Trace fear conditioning traning consisted of a 15-sec white noise conditioned stimulus (CS) and a 0.5 s scrambled foot shock (US). Mice were acclimated for 60 sec and then presented with seven CS-trace-US intertrial interval trials ( trace, 30 sex, ITI, 210 sec). One day after training, mice were acclimated for 60 Sec followed by 7 CS ITI trials ( ITI, 30 sec) in a novel chamber to test for trace
 Trace fear conditioning
 PND 29
Eye blink conditioning behavior1
Decreased
Description: Percentage of eye blink conditioned respones was significantly reduced.
 
 
Passive avoidance behavior6
Decreased
Description: Decreased passive-avoidance behavior; Ameliorated by chronic lithium administration
Exp Paradigm: Measure of latency to cross to a dark side whereupon the mice receive a single foot-shock
 
 ~3 months
Reward reinforced choice behavior1
Decreased
Description: Fmr1 KO mice show reduced learning in the conditional cue dependent choice task, WT mice progressively learned the task
Exp Paradigm: Y maze learning test was carried out using an elevated Y maze, one start arma nd two goal arms. The food well located at the end of each goal arm was filled with sucrose sweetened non fat dairy milk as a reward. After 18 h food fasting with no restriction on water access, mice were first habituated to Y maze and milk reward. MIce were then trained and tested on a conditional learning task using in
 Y maze with food bait
 PND 29
Cued or contextual fear conditioning1
Decreased
Description: Fmr1 KO mice show reduced (but insignificant) freezing in the contextual fear conditioning paradigm comapred to WT controls
Exp Paradigm: The standard fear conditioning training consisted of a 3 min exposure of mice to conditioning box (Context) followed by a foot shock, after a preceding tone (30 s, 3kHz, 75dB). The memory test is performed after 24 h by re exposing the animals for 5 min to the conditining context and 1 h later to a novel context for 3 min followed by a tone( 3 min, 3 kHz, 75 dB)
 Contextual fear conditioning
 PND 29
Spatial Learning2
Decreased
Description: Highly significant decrease in escape latency
Exp Paradigm: Hidden platform condition of Morris water maze task
 
 
Anxiety1
Decreased
Description: Fmr1 KO mice spend more time in the light chamber and have more gate crossings showing reduced anxiety
Exp Paradigm: The dark chamber was not illuminated and the light chamber was illuminated with a fluorescent light. Mice were placed in the dark chamber for 2 min. The divider separating the two chambers was then removed and the mice were allowed to freely investigate both chambers for 10 min. The time spent in the light chamber and the number of gate crossings in the light-dark box were recorded
 Light dark two chamber box
 PND 29
Anxiety1
Decreased
Description: Fmr1 KO mice spend more time in the open arms in the elevated plus maze showing reduced anxiety
Exp Paradigm: Time spent in the open arms of the plus maze was recorded. Mice were placed in the center of the maze and allowed to freely explore the covered and the open arms
 Elevated plus maze
 PND 29
Ultrasonic Vocalization Properties1
 No change
 Vocalization analysis
 
Lethality15
 No Change
 General Observations
 2.5 - 6 months
Mating Behavior11
 No change
 Mating behavior observation
 
Reproductive Ability2
 No Change
 
 Unreported
Depression6
 No Change
 
 ~3 months
Homeostasis5
 No Change
 ELISA
 
Cued conditioning anamolies2
 No Change
 
 
Object Recognition Memory15
 No Change
 Novel object recognition test
 2.5 - 6 months
Spatial Learning15
 No Change
 Water maze task
 2.5 - 6 months
Spatial Learning2
 No Change
 
 
Spatial Reference Memory5
 No Change
 Morris Water Maze
 60-120 days
Spatial Reference Memory5
 No Change
 Plus-shaped Water Maze
 60-120 days
Dopamine Release13
 No change
 Fixed potential amperometry
 
G-quartet containing bound mRNA expression3
 No Change
 
 Unreported
G-quartet containing bound mRNA expression3
 No Change
 Real-time PCR
 Unreported
GABAA receptor subunit protein localization3
 No Change
 
 17 weeks
GABAA receptor subunit 1 protein localization3
 No Change
 
 17 weeks
Gene expression profile3
 No Change
 
 Unreported
Gene expression profile3
 No Change
 Microarray analysis
 Unreported
mTOR Kinase Activity7
 No Change
 Western Blot analysis and immunoprecipitation followed by immunoblotting
 4-6 weeks
mTOR Phosphorylation7
 No Change
 Western Blot analysis
 4-6 weeks
mTOR protein expression7
 No Change
 Western Blot analysis
 4-6 weeks; 6-8 months
Protein Expression15
 No Change
 Immunohistochemical analysis
 2.5 - 6 months
General Locomotor Activity5
 No Change
 Open Field test
 
General Locomotor Activity10
 No change
 Open Field Test
 
Swimming6
 No Change
 
 ~3 months
Brain Development5
 No Change
 Immunohistochemistry
 
Brain Morphology4
 No Change
 Double immunohistochemistry
 PD365-380
Brain Morphology4
 No Change
 Double immunohistochemistry
 PD365-380
Brain Size2
 No Change
 
 60-70 days
Basal Synaptic Properties10
 No change
 
 
Long Term Depression9
 No change
 Short-term depression
 4-5 weeks
Synaptic Connections9
 No change
 
 4-5 weeks
Aggression15
 No Change
 Resident-intruder paradigm
 2.5 - 6 months
Grooming8
 No change
 Social interaction apparatus
 3 months
Sociability8
 No change
 Social Interaction apparatus
 3 months
Social Approach8
 No change
 Social Interaction apparatus
 3 months
Social Approach8
 No change
 Social Interaction apparatus
 3 months
Social Interaction8
 No change
 Social Interaction apparatus
 3 months
Social Interaction8
 No change
 Social Interaction apparatus
 3 months
Social Interaction2
 No Change
 
 Unreported
 Not Reported: Circadian sleep/wake cycle ,   Circadian sleep/wake cycle ,   Communications ,   Communications ,   Developmental profile ,   Emotion ,   Emotion ,   Homeostasis ,   Homeostasis ,   Immune Response ,   Immune Response ,   Inflammatory response ,   Learning & memory ,   Maternal behavior ,   Maternal behavior ,   Molecular profile ,   Motor phenotype ,   Neuroanatomy / Ultrastructure / Cytoarchitecture ,   Neurophysiology ,   Neurophysiology ,   Neurophysiology ,   Repetitive behavior ,   Repetitive behavior ,   Seizure ,   Seizure ,   Sensory ,   Sensory ,   Social behavior ,  

FMR1_3_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Reproductive Ability2
Abnormal
Description: Increased testis weights
 
 
Reproductive Ability2
Abnormal
Description: Macroorchidism
Exp Paradigm: General Observation
 General Observation
 Unreported
Population spike1
Increased
Description: Brain slices extracted from early postnatal Fmr1 KO pups show increased field potential recordings after treatment with GABAa R agonist: isoguvacine, unlike slices from WT littermates
Exp Paradigm: Field potential recordings of slices treated with isoguvacine
 Field potential recordings
 PND 15
Spontaneous post synaptic events1
Increased
Description: Hippocampal slices of newborn and young Fmr1 KO pups showed bursting activity and a four-fold increase in spontaneous excitatory postsynaptic currents
 Whole cell voltage clamp
 P0, PND 15
Action potential firing1
Increased
Description: Neurons extracted from newborn Fmr1 KO pups show increased spike ( action potential) frequencies when treated with the GABAa R agonist: isoguvacine, unlike WT littermate neurons, that did not show an increased spike frequency following the treatment.
Exp Paradigm: Cell attached recordings of slices treated with isoguvacine
 Cell attached recordings
 P0
Driving force of ion channel or receptor1
Increased
Description: Fmr1 KO mice show a continued elevated driving force of GABAa receptor (Chloride ion channel) in fetal neurons from embryonic day 20- 21 through post natal day 15 and 30, unlike WT littermates who had elevated driving force only during the embryonic stages and showed a reduction in the driving force in early post natal stages.
 
 E 20,21; P15; 30
Neuron specific transporter expression and activity1
Decreased
Description: Fmr1 KO mice show reduced expression of KCC2 chloride exporter channels in the hippocampi compared to WT littermates.
 Immuno-cytochemistry, Fluoroscent microscopy
 PND15
Fmrp expression2
Decreased
Description: No Fmrp signal in brain and spermatogonia
Exp Paradigm: Immunocytochemistry of brain and testis using antibody against Fmrp
 
 
Fmr1 gene expression2
Decreased
Description: Decreased Fmr1 gene expression
Exp Paradigm: Quantitative PCR of cDNA generated from RNA isolated in the brain
 Quantitative PCR of cDNA generated from RNA isolated in the brain
 Unreported
Fmrp expression2
Decreased
Description: Total absence of Fmrp expression in total brain lysates.
Exp Paradigm: Western Blot analysis of homogenized brain lysate
 
 
Fmr1 gene expression2
Decreased
Description: Drastically reduced levels of Fmr1 transcripts in brain
Exp Paradigm: Quantitative PCR of cDNA generated from RNA isolated in the brain
 
 
Fmrp expression2
Decreased
Description: Decreased Fmrp expression
Exp Paradigm: Immunocytochemistry of brain and testis using antibody against Fmrp
 Immunocytochemistry of brain and testis using antibody against Fmrp
 Unreported
Fmrp expression2
Decreased
Description: Decreased Fmrp expression
Exp Paradigm: Western Blot analysis of homogenized brain lysate
 Western Blot analysis of homogenized brain lysate
 Unreported
Ultrasonic vocalization1
Abnormal
Description: Fmr1KO pups had a higher probability of emitting downward and chevron calls than control pups.
 Isolation induced ultrasonic vocalization
 PND8
Normal Phenotype2
 No Change
 General observation
 Unreported
Normal Phenotype2
 No Change
 
 
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Emotion ,   Homeostasis ,   Immune response ,   Inflammatory response ,   Learning & memory ,   Maternal behavior ,   Motor phenotype ,   Neuroanatomy / Ultrastructure / Cytoarchitecture ,   Neurophysiology ,   Repetitive behavior ,   Seizure ,   Sensory ,   Social behavior ,  

FMR1_4_CN_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Reproductive Ability1
Macroorchidism
Description: Increased testis weights
 
 
Reproductive Ability1
Abnormal
Description: Macroorchidism
Exp Paradigm: General Observation
 General Observation
 Unreported
Fmrp expression1
Decreased
Description: Decreased Fmrp expression
Exp Paradigm: Immunocytochemistry of brain and testis using antibody against Fmrp; Crossed with specific promoter limiting cre expression to Purkinje neurons
 Immunocytochemistry of brain and testis using antibody against Fmrp; Crossed with specific promoter limiting cre expression to Purkinje neurons
 Unreported
Fmrp expression1
Decreased
Description: Absence of Fmrp in Purkinje cells but positive staining in cells of neuronal and glial lineage
Exp Paradigm: Immunocytochemistry of brain and testis using antibody against Fmrp; Crossed with specific promoter limiting cre expression to Purkinje neurons
 
 
Normal phenotype1
 No Change
 General Observation
 Unreported
Normal phenotype1
 No Change
 
 
Fmr1 gene expression1
 No Change
 Quantitative PCR of cDNA generated from RNA isolated in the brain
 Unreported
Fmr1 gene expression1
 No Change
 
 
Fmrp expression1
 No Change
 Western Blot analysis of homogenized total brain lysates
 Unreported
Fmrp expression1
 No Change
 
 
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Emotion ,   Homeostasis ,   Immune response ,   Inflammatory response ,   Learning & memory ,   Maternal behavior ,   Motor phenotype ,   Neuroanatomy / Ultrastructure / Cytoarchitecture ,   Neurophysiology ,   Repetitive behavior ,   Seizure ,   Sensory ,   Social behavior ,  

FMR1_2_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Size/Growth6
Abnormal
Description: macroorchidism
Exp Paradigm: General Observation; Light microscopic examination
 General Observation; Light microscopic examination
 40-50; 60-70; 90-100; 160-170 days
Testis Weight5
Increased
Description: Increased testis weight
Exp Paradigm: General Observations
 General Observations
 5-17 weeks
Seizure5
Increased
Description: Increased seizure response to intense auditory stimuli
Exp Paradigm: Response to intense auditory stimuli (120 dB)
 Response to auditory stimuli
 
Homeostasis3
Decreased
Description: Decreased corticosterone levels after acute stress
Exp Paradigm: Corticosterone Enzyme Immunoassay Kit on trunk blood serum after 3-h restraint procedure
 ELISA
 
Long Term Depression5
Increased
Description: Increased Gp1 mGlu-mediated hippocampal LTD
Exp Paradigm: Extracellular field potentials were recorded in stratum radiatum of CA1 in response to Schaffer collateral stimulation from hippocampal slices
 Extracellular field potential recordings
 P25-P30
Maximum Transient Depression5
Increased
Description: Increased maximum transient depression (MTD) in response to DHPG
Exp Paradigm: Extracellular field potentials were recorded in stratum radiatum of CA1 in response to Schaffer collateral stimulation from hippocampal slices
 Extracellular field potential recordings
 P58-P65
Synaptic Transmission2
Decreased
Description: Decreased glycine-induced Long Term Potentiation in hippocampal slices
 Field-potential recording
 
Brain Development3
Decreased
Description: Decreased neuronal cell survival in the ventral dentate gyrus
Exp Paradigm: BrdU immunohistochemical analysis
 Immunohistochemistry
 
Spine Density5
Increased
Description: Increased spine density in pyramidal neurons of binocular visual cortex in basal dendrites
Exp Paradigm: Golgi Analysis
 Golgi Analysis
 
BDNF Protein expression4
Increased
Description: Increased BDNF expression in hippocampal extracts after chronic lithium treatment
Exp Paradigm: ELISA
 ELISA
 ~3 months
Serine-phosphorylation of GSK3 protein4
Increased
Description: Increase in phospho-Ser21-GSK3 and phospho-Ser9-GSK3 after 30 min of MPEP treatment in the striatum, hippocampus, cerebral cortex, and cerebellum; Sustained increase in phospho-Ser9-GSK3 selectively in striatum after 90 min; No change in total levels of GSK3 or GSK3
Exp Paradigm: Immunoblot analysis of brain extracts treated with 30mg/kg of MPEP, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 Immunoblot analysis of brain extracts treated with 30mg/kg of MPEP, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 ~3 months
Intracellular Signaling5
Abnormal
Description: Abnormal intracellular signaling in cerebral cortex indicated by increased ERK & mTOR phosphorylation
Exp Paradigm: Western Blot Analysis
 Western Blot analysis
 
Protein synthesis levels5
Increased
Description: Increased rate of protein synthesis
Exp Paradigm: Measurement of 35S-methionine/cysteine incorporation in acute hippocampal slices
 35S Methionine/Cysteine incorporation
 
Serine-phosphorylation of GSK3 protein4
Increased
Description: Increase in both phospho-Ser9-GSK3 and phospho-Ser21-GSK3 after chronic treatment with lithium in striatum, hippocampus, cerebral cortex, and cerebellum
Exp Paradigm: Immunoblot analysis of brain extracts treated with 4mmole/kg of lithium, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 Immunoblot analysis of brain extracts treated with 4mmole/kg of lithium, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 ~3 months
Basal levels and phosphorylation of GSK3 protein4
Decreased
Description: Decreased phosphorylation on inhibitory serines in the striatum, cerebral cortex, and hippocampus; No change in levels in cerebellum; No change in total levels of both isoforms of GSK3
Exp Paradigm: Immunoblot analysis of brain extracts using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 Immunoblot analysis of brain extracts using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 ~3 months
Serine-phosphorylation of GSK3 protein4
Increased
Description: Increase in both phospho-Ser9-GSK3 and phospho-Ser21-GSK3 after treatment with lithium in striatum, hippocampus, cerebral cortex, and cerebellum after 30 minutes; Sustained increase after 90 minutes observed only in cerebellum
Exp Paradigm: Immunoblot analysis of brain extracts treated with 4mmole/kg of lithium, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 Immunoblot analysis of brain extracts treated with 4mmole/kg of lithium, using antibodies towards phospho-Ser9-GSK3 and phospho-Ser21-GSK3
 ~3 months
General Locomotor Activity5
Increased
Description: Increased novelty-induced locomotor activity
Exp Paradigm: Open Field Test
 Open Field Test
 2-5 months
Hyperactivity4
Increased
Description: Increased hyperactivity; Abolished by administration of lithium; Increased center-square behavior in open field; Reduced by administration of lithium
Exp Paradigm: Open field test
 Open field test
 ~3 months
Spontaneous Movement6
Increased
Description: Increased spontaneous movement
Exp Paradigm: Number of crossing through three infrared beams in an empty cage
 Number of crossing through three infrared beams in an empty cage
 Unreported
Acoustic Startle Reflex5
Increased
Description: Increased acoustic startle reflex manifesting as whole body startle response
Exp Paradigm: Response to short auditory stimuli of moderate intensity
 Response to auditory stimuli
 
Cued Fear Conditioning5
Decreased
Description: Decreased cued fear conditioning indicated by reduced latency to enter the dark compartment
Exp Paradigm: Inhibitory avoidance paradigm
 Inhibitory avoidance paradigm
 
Passive avoidance behavior4
Decreased
Description: Decreased passive-avoidance behavior; Ameliorated by chronic lithium administration
Exp Paradigm: Measure of latency to cross to a dark side whereupon the mice receive a single foot-shock
 Measure of latency to cross to a dark side whereupon the mice receive a single foot-shock
 ~3 months
Spatial Learning6
Decreased
Description: Decreased spatial learning
Exp Paradigm: Hidden platform condition of Morris water maze task
 Hidden platform condition of Morris water maze task
 Unreported
Reproductive Ability6
 No Change
 General Observation
 Unreported
Depression4
 No Change
 Tail suspension test
 ~3 months
Homeostasis3
 No Change
 ELISA
 
Cued conditioning anomalies6
 No Change
 Passive Avoidance Task
 Unreported
Spatial Learning6
 No Change
 Visible platform condition of Morris water maze task
 Unreported
Spatial Reference Memory3
 No Change
 Morris Water Maze
 60-120 days
Spatial Reference Memory3
 No Change
 Plus-shaped Water Maze
 60-120 days
General Locomotor Activity3
 No Change
 Open Field test
 
Swimming4
 No Change
 Forced swin test
 ~3 months
Brain Development3
 No Change
 Immunohistochemistry
 
Brain Size6
 No Change
 Macroscopic analysis; Light microscopic analysis; Immunohistochemical analysis
 60-70 days
Social Interaction6
 No Change
 Direct contacts between genotypically identical pairs test
 Unreported
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Developmental profile ,   Emotion ,   Homeostasis ,   Immune Response ,   Learning & memory ,   Maternal behavior ,   Molecular profile ,   Motor phenotype ,   Neuroanatomy / Ultrastructure / Cytoarchitecture ,   Neurophysiology ,   Repetitive behavior ,   Seizure ,   Sensory ,   Social behavior ,  

FMR1_6_I304N_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Macroorchidism1
Increased
Description: Increased macroorchidism
Exp Paradigm: General Observations
 General Observations
 Unreported
Repetetive Behavior1
Increased
Description: Increase repetitive behavior as measured by marble burying
Exp Paradigm: Marble burying test indicative of repetitive behavior
 Marble burying test
 Unreported
General Locomotor Activity1
Increased
Description: Increased general locomotor activity
Exp Paradigm: Open field test for activity
 Open Field test
 Unreported
Pain1
Decreased
Description: Decreased sensitiity to pain
Exp Paradigm: Hot plate test for a measure of pain sensitivity
 Hot plate test
 Unreported
General Characteristics1
 No Change
 General Observations
 Unreported
Size/Growth1
 No Change
 General Observations
 Unreported
Rearing1
 No Change
 Open field test
 Unreported
Pre-pulse inhibition1
 No Change
 
 
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Homeostasis ,   Immune Response ,   Learning & memory ,   Maternal behavior ,   Molecular profile ,   Neuroanatomy / Ultrastructure / Cytoarchitecture ,   Neurophysiology ,   Seizure ,   Social behavior ,  

FMR1_5_KI_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Developmental Trajectory1
Increased
Description: Increased testes weight
Exp Paradigm: General Observations
 General Observations
 Unreported
Dendritic Spine Morphology1
Increased
Description: Increased dendritic spine density in neurons in medial prefrontal cortex, dorsal hippocampus, basal lateral amygdala
Exp Paradigm: Quantification of spines on golgi-cox stained secondary apical and primary basal dendrites of layer III pyramidal cells in medial prefrontal cortex, CA3 pyramidal cells in dorsal hippocampus, pyramidal-like and stellate cells in basal lateral amygdala
 Golgi-Cox Staining
 17 weeks
Dendrite Morphology1
Decreased
Description: Decreased arborization of dendrites in Layer III pyramidal neurons, CA3 pyramidal cells, and pyramidal and stellate cells in basal lateral amygdala
Exp Paradigm: Golgi-Cox staining of neurons in medial prefrontal cortex, hippocampus, and basal lateral amygdala
 Golgi-Cox Staining
 17 weeks
Fmr1 mRNA expression1
Increased
Description: Increased levels of Fmr1 mRNA throught the brain
Exp Paradigm: Qualitative Polymerase Chain Reaction on RNA samples
 qPCR
 3 months
FMRP protein expression1
Decreased
Description: Decreased levels of FMRP protein throughout brain
Exp Paradigm: Western Blot analysis of sample derived throughout brain
 Western Blot analysis
 3 months
Cerebral Protein Synthesis Rate1
Increased
Description: Increased rate of cerebral protein synthesis (rCPS) as measured across various brain regions including dorsal/ventral hippocampus and cortical areas
Exp Paradigm: Autoradiographic L-[1-14C]leucine mediated measurement of rCPS
 Autoradiographic Analysis
 17 weeks
Social Interaction1
Abnormal
Description: Abnormal social interaction demonstrated by no change in behavior during social approach but abnormality during social novelty
Exp Paradigm: Three chambered social approach test apparatus
 Three-chamber apparatus
 8-10 weeks
General Locomotor Activity1
Increased
Description: Increased horizontal distance traveled indicated increased general locomotor activity i.e. hyperactivity
Exp Paradigm: Open field test
 Open Field test
 7-9 weeks
Cued conditioning1
Decreased
Description: Decreased cued conditioning learning and memory deficit performance
Exp Paradigm: Passive avoidance task
 Passive avoidance task
 13-16 weeks
General Characteristics1
 No Change
 General Observations
 Unreported
Size/Growth1
 No Change
 General Observations
 Unreported
Anxiety1
 No Change
 Elevated plus maze test
 Unreported
Motor coordination1
 No Change
 Rotarod test
 Unreported
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Homeostasis ,   Immune Response ,   Maternal behavior ,   Neurophysiology ,   Repetitive behavior ,   Seizure ,   Sensory ,  

FMR1_7_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Testis Weight2
Increased
Description: Increased testis weight
Exp Paradigm: General Observations
 General Observations
 10-17 weeks
Seizure2
Increased
Description: Increased susceptibility to sound-induced seizures indicated by sequential seizure response of wild running, tonic-clonic seizures, and respiratory arrest, leading to death
Exp Paradigm: Audiogenic seizure assay
 Audiogenic seizure assay
 10-17 weeks
Dendritic Spine Density2
Increased
Description: Increased mean density of apical dendritic spines in segment 3 without changes in segments 1-2 and 5-10
Exp Paradigm: Golgi staining procedure of pyramidal cells in cortical layers II/III of temporal lobe
 Golgi staining
 11 weeks
Kinase Phosphorylation levels3
Decreased
Description: Decreased phosphorylation levels of GSK3alpha in hippocampus
Exp Paradigm: Multi-kinase ELISA array
 Multi-kinase ELISA array
 
Kinase Phosphorylation levels3
Increased
Description: Increased phosphorylation levels of Akt1, Akt2 and ERk1/2 in hippocampus
Exp Paradigm: Multi-kinase ELISA array
 Multi-kinase ELISA array
 
Stereotypies3
Increased
Description: Increased levels of stereotypy counts
Exp Paradigm: Open Field Test
 Open Field Test
 
Stereotypies2
Increased
Description: Increased levels of stereotypy counts
Exp Paradigm: Open Field Test
 Open Field Test
 10-17 weeks
Burying3
Increased
Description: Increased burying behavior
Exp Paradigm: Marble burying assay
 Marble burying assay
 4, 8 weeks; 2 months
Circling2
Increased
Description: Increased circling demonstrated by more revelving in counterclockwise direction
Exp Paradigm: Open Field Test
 Open Field Test
 10-17 weeks
General Locomotor Activity3
Increased
Description: Increased locomotor activity indicated by more total arm entries
Exp Paradigm: Elevated plus maze test
 Elevated plus maze test
 4, 8 weeks
General Locomotor Activity1
Increased
Description: Increased spontaenous locomotor activity demonstrated by greater distance traveled and greater average velocity
Exp Paradigm: Open field test
 Open Field test
 3 months
General Locomotor Activity2
Increased
Description: Increased locomotor activity indicated by greater distance traveled, more distinct horizontal movement, and more time spent moving
Exp Paradigm: Open Field Test
 Open Field Test
 10-17 weeks
General Locomotor Activity3
Increased
Description: Increased locomotor activity indicated by more line crosses
Exp Paradigm: Open Field Test
 Open Field Test
 4, 8 weeks
Acoustic Startle Reflex1
Decreased
Description: Decreased acoustic startle reflex
Exp Paradigm: Acoustic Startle Reflex after intraperitoneal administration of THIP (10 mg/kg)
 Acoustic Startle Reflex after THIP administration
 3 months
Sensorimotor Gating1
Increased
Description: Increased sensorimotor gating measured by prepulse inhibition with all prepulses, but more pronounced with lower decibel
Exp Paradigm: Prepulse inhibition test
 Prepulse inhibition test
 3 months
Acoustic Startle Reflex1
Decreased
Description: Decreased acoustic startle reflex
Exp Paradigm: Acoustic Startle Reflex
 Acoustic Startle Reflex
 3 months
Cued Fear Conditioning1
Decreased
Description: Decreased cued conditioning learning measured as freezing patterms
Exp Paradigm: Cued Fear Conditioning Test
 Cued Fear Conditioning Test
 3 months
Cued Fear Conditioning1
Decreased
Description: Decreased cued conditioning learning measured as freezing patterms
Exp Paradigm: Cued Fear Conditioning Test after intraperitoneal administration of THIP (10 mg/kg)
 Cued Fear Conditioning Test after THIP administration
 3 months
Body Weight Gain2
 No change
 General Observations
 10-17 weeks
Anxiety1
 No change
 Open Field test
 3 months
IgG levels3
 No change
 
 
Contextual Fear Conditioning1
 No change
 Contextual Fear Conditioning test
 3 months
General Locomotor Activity1
 No change
 Open Field test after THIP administration
 3 months
Dendritic Spine Density2
 No change
 Golgi staining
 11 weeks
Sensorimotor Gating1
 No change
 Prepulse inhibition test after THIP administration
 3 months
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Developmental profile ,   Emotion ,   Homeostasis ,   Immune Response ,   Learning & memory ,   Maternal behavior ,   Molecular profile ,   Neuroanatomy / Ultrastructure / Cytoarchitecture ,   Neurophysiology ,   Repetitive behavior ,   Seizure ,   Sensory ,   Social behavior ,  

FMR1_8_KO_HM

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Developmental Trajectory1
Abnormal
Description: Abnormal developmental trajectory demonstrated by increased testicular weights
Exp Paradigm: General Observations
 General Observations
 P90-100
Weight gain1
Increased
Description: Increased rate of weight gain
Exp Paradigm: General Observations
 General Observations
 6 weeks
Long Term Depression1
Increased
Description: Increased induction of mGluR long term depression in hippocampus
Exp Paradigm: Whole cell recordings of hippocampal slices after bath application of DHPG
 Whole cell recordings
 P23-P35
Dendritic Spine Density1
Increased
Description: Increased spine density in pyramidal neurons in hippocampal area CA1
Exp Paradigm: Golgi Staining procedure of pyramidal neurons in hippocampal area CA1
 Golgi staining
 P90-100
Dendritic Spine Morphology1
Abnormal
Description: Abnormal spine morphology of pyramidal neurons in hippocampal area CA1 with higher fraction of fliopodia-like and thin spines compared to stubby and mushroom spines
Exp Paradigm: Golgi Staining procedure of pyramidal neurons in hippocampal area CA1
 Golgi staining
 P90-100
S6 phosophorylation level1
Increased
Description: Increased levels of phosphorylated S6 in hippocampal area CA1
Exp Paradigm: Immunohistochemical analysis using hippocampal section stained for p-S6-240/44 and 235/36 in pyramidal neurons of area CA1
 Immunohistochemical analysis
 8-10 weeks
Phosphorylation State1
Increased
Description: Increased phosphorylation of key translational control molecules - S6 at 240/244 and 235/36 phosphorylation sites, eIF4B, mTOR, ERK in whole hippocampal lysates
Exp Paradigm: Western blots of whole hippocampal lysates
 Western Blot analysis
 
Protein Expression Levels1
Abnormal
Description: Increased levels of expression of synaptic proteins PSD-95, CaMKIIa, Shank3; translation factors eIF4G, eEF2
Exp Paradigm: Western Blot analysis of whole hippocampal lysates
 Western Blot analysis
 
Protein synthesis levels1
Increased
Description: Increased protein synthesis levels in hippocampal slices measured through levels of puromycin labeling
Exp Paradigm: SUnSET nonradioactive puromycin end-labeling assay to measure protein synthesis
 SUnSET assay
 
Social Approach1
Abnormal
Description: Abnormal social approach indicated by failure to distinguish familiar from novel mice
Exp Paradigm: Three-chambered social interaction test
 Three-chambered social interaction test
 
Repetitive Behavior1
Increased
Description: Increased repetitive behavior measured through number of marbles buried
Exp Paradigm: Marble burying assay
 Marble burying assay
 
Motor coordination1
Decreased
Description: Decreased motor coordination
Exp Paradigm: Rotarod Test
 Rotarod test
 
Spatial Working Memory1
Decreased
Description: Decreased spatial working memory as assayed through reversal learning
Exp Paradigm: water based Y-maze test
 Water based Y-maze test
 
Object Recognition Memory1
Decreased
Description: Decreased novel object recognition memory
Exp Paradigm: Novel object recognition test
 Novel object recognition test
 
Spatial Working Memory1
 No change
 Water based Y-maze test
 
Protein Expression Levels1
 No change
 Western Blot analysis
 
 Not Reported: Circadian sleep/wake cycle ,   Communications ,   Homeostasis ,   Immune Response ,   Maternal behavior ,   Seizure ,   Sensory ,  

Fmr1_1_KO_HM_5HT2bAG+D1AG+PI3K inhibitor

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Cued or contextual fear conditioning1
Decreased
Description: Treatment with a PI3 K inhibitor eliminates the benefits of treatment with the cocktail of 5HT and Dopamine agonists and reduces learning mediated freesing to the level of Fmr1 KO mice
Exp Paradigm: Trace fear conditioning traning consisted of a 15-sec white noise conditioned stimulus (CS) and a 0.5 s scrambled foot shock (US). Mice were acclimated for 60 sec and then presented with seven CS-trace-US intertrial interval trials ( trace, 30 sex, ITI, 210 sec). One day after training, mice were acclimated for 60 Sec followed by 7 CS ITI trials ( ITI, 30 sec) in a novel chamber to test for trace
 Trace fear conditioning
 PND 29
Reward reinforced choice behavior1
Decreased
Description: Treatment with a PI3 K inhibitor construct instead of GluA1 eliminates the benefits of treatment with the cocktail of 5HT and Dopamine agonists and reduces cue conditioned choice learning to the level of Fmr1 KO mice
Exp Paradigm: Y maze learning test was carried out using an elevated Y maze, one start arma nd two goal arms. The food well located at the end of each goal arm was filled with sucrose sweetened non fat dairy milk as a reward. After 18 h food fasting with no restriction on water access, mice were first habituated to Y maze and milk reward. MIce were then trained and tested on a conditional learning task using in
 Y maze with food bait
 PND 29
 Not Reported:

Fmr1_1_KO_HM_GluA1CT-5HT2bAG+D1AG

Category
Entity
Quantity
Experimental Paradigm
Age at Testing
Cued or contextual fear conditioning1
Decreased
Description: Infecting with the dominant negative GluA1 CT construct instead of GluA1 eliminates the benefits of treatment with the cocktail of 5HT and Dopamine agonists and reduces learning mediated freezing to the level of Fmr1 KO mice
Exp Paradigm: Trace fear conditioning traning consisted of a 15-sec white noise conditioned stimulus (CS) and a 0.5 s scrambled foot shock (US). Mice were acclimated for 60 sec and then presented with seven CS-trace-US intertrial interval trials ( trace, 30 sex, ITI, 210 sec). One day after training, mice were acclimated for 60 Sec followed by 7 CS ITI trials ( ITI, 30 sec) in a novel chamber to test for trace
 Trace fear conditioning
 PND 29
Reward reinforced choice behavior1
Decreased
Description: Infecting with the dominant negative GluA1 CT construct instead of GluA1 eliminates the benefits of treatment with the cocktail of 5HT and Dopamine agonists and reduces cue conditioned choice learning to the level of Fmr1 KO mice
Exp Paradigm: Y maze learning test was carried out using an elevated Y maze, one start arma nd two goal arms. The food well located at the end of each goal arm was filled with sucrose sweetened non fat dairy milk as a reward. After 18 h food fasting with no restriction on water access, mice were first habituated to Y maze and milk reward. MIce were then trained and tested on a conditional learning task using in
 Y maze with food bait
 PND 29
 Not Reported:



Interactor Symbol Interactor Name Interactor Organism Entrez ID Uniprot ID Interaction Type Evidence Reference
AAAS achalasia, adrenocortical insufficiency, alacrimia 8086 Q9NRG9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AAGAB alpha- and gamma-adaptin binding protein 79719 Q6PD74 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AAMP angio-associated, migratory cell protein 14 Q13685 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AARS alanyl-tRNA synthetase 16 P49588 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AARS2 alanyl-tRNA synthetase 2, mitochondrial 57505 Q5JTZ9 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AARSD1 alanyl-tRNA synthetase domain containing 1 80755 Q9BTE6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AASDH aminoadipate-semialdehyde dehydrogenase 132949 Q4L235 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AASDHPPT aminoadipate-semialdehyde dehydrogenase-phosphopantetheinyl transferase 60496 Q9NRN7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AASS aminoadipate-semialdehyde synthase 10157 A4D0W4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AATF apoptosis antagonizing transcription factor 26574 Q9NY61 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABAT 4-aminobutyrate aminotransferase 18 P80404 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCA13 ATP-binding cassette, sub-family A (ABC1), member 13 154664 Q86UQ4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCA4 ATP-binding cassette, sub-family A (ABC1), member 4 24 P78363 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCA5 ATP-binding cassette, sub-family A (ABC1), member 5 23461 Q8WWZ7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCB10 ATP-binding cassette, sub-family B (MDR/TAP), member 10 23456 Q9NRK6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 22 O75027 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCC1 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 4363 P33527 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCC10 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 89845 Q5T3U5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 8714 O15438 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 10257 O15439 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCC5 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 10057 O15440 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCD3 ATP-binding cassette, sub-family D (ALD), member 3 5825 P28288 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCE1 ATP-binding cassette, sub-family E (OABP), member 1 6059 P61221 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABCF1 ATP-binding cassette, sub-family F (GCN20), member 1 23 Q8NE71 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ABCF2 ATP-binding cassette, sub-family F (GCN20), member 2 10061 Q75MJ1 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ABHD10 abhydrolase domain containing 10 55347 Q9NUJ1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABHD12 abhydrolase domain containing 12 26090 Q8N2K0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABHD13 abhydrolase domain containing 13 84945 Q7L211 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABHD15 abhydrolase domain containing 15 116236 Q6UXT9 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ABHD16A abhydrolase domain containing 16A 7920 B3KNX9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABHD2 abhydrolase domain containing 2 11057 P08910 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABHD5 abhydrolase domain containing 5 51099 Q8WTS1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABHD8 abhydrolase domain containing 8 79575 B2C6G3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABI1 abl-interactor 1 10006 Q8IZP0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABI2 ?abl-interactor 2 10152 Q9NYB9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABL1 c-abl oncogene 1, non-receptor tyrosine kinase 25 P00519 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ABL2 v-abl Abelson murine leukemia viral oncogene homolog 2 27 P42684 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABLIM1 actin binding LIM protein 1 3983 B3KSG3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABT1 activator of basal transcription 1 29777 Q9ULW3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ABTB2 ankyrin repeat and BTB (POZ) domain containing 2 25841 Q8N961 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAA2 acetyl-CoA acyltransferase 2 10449 B3KNP8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACACA acetyl-CoA carboxylase alpha 31 Q13085 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACACB acetyl-CoA carboxylase beta 32 O00763 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAD10 acyl-CoA dehydrogenase family, member 10 80724 Q6JQN1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAD9 acyl-CoA dehydrogenase family, member 9 28976 Q9H845 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACADL acyl-CoA dehydrogenase, long chain 33 P28330 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain 34 P11310 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAP2 ArfGAP with coiled-coil, ankyrin repeat and PH domains 2 23527 Q15057 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAP3 ArfGAP with coiled-coil, ankyrin repeat and PH domains 3 116983 Q8WTZ1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAT1 acetyl-CoA acetyltransferase 1 38 P24752 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACAT2 acetyl-CoA acetyltransferase 2 39 Q9BWD1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACBD5 acyl-CoA binding domain containing 5 91452 Q5T8D3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACBD6 acyl-CoA binding domain containing 6 84320 B2RAA8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACER3 alkaline ceramidase 3 55331 Q9NUN7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACIN1 apoptotic chromatin condensation inducer 1 22985 Q9UKV3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACN9 ACN9 homolog (S. cerevisiae) 57001 Q9NRP4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACO1 aconitase 1, soluble 48 P21399 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACOT9 acyl-CoA thioesterase 9 23597 Q9Y305 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACOX1 acyl-CoA oxidase 1, palmitoyl 51 B4DK61 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACP1 acid phosphatase 1, soluble 52 B5MCC7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACP2 acid phosphatase 2, lysosomal 53 P11117 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ACP6 acid phosphatase 6, lysophosphatidic 51205 Q9NPH0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACSF3 acyl-CoA synthetase family member 3 197322 Q4G176 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACSL1 acyl-CoA synthetase long-chain family member 1 2180 P33121 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACSL3 acyl-CoA synthetase long-chain family member 3 2181 B3KMA6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACSL4 acyl-CoA synthetase long-chain family member 4 2182 O60488 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACSS1 acyl-CoA synthetase short-chain family member 1 84532 Q9NUB1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTA1 ?actin, alpha 1, skeletal muscle 58 P68133 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTG1 actin, gamma 1 71 P63261 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTL6A actin-like 6A 86 O96019 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTN1 actinin, alpha 1 87 P12814 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ACTN4 actinin, alpha 4 81 O43707 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ACTR1A ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) 10121 P61163 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTR1B ARP1 actin-related protein 1 homolog B, centractin beta (yeast) 10120 P42025 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTR2 ARP2 actin-related protein 2 homolog (yeast) 10097 E9PF41 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTR3 ARP3 actin-related protein 3 homolog (yeast) 10096 P61158 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTR3B ARP3 actin-related protein 3 homolog B (yeast) 57180 Q59GD5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACTR8 ARP8 actin-related protein 8 homolog (yeast) 93973 Q9H981 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACVR1 activin A receptor, type I 90 D3DPA4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACVR1B activin A receptor, type IB 91 P36896 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ACVR2A activin A receptor, type IIA 92 P27037 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ACVR2B activin A receptor, type IIB 93 Q13705 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAL adenosine deaminase-like 161823 Q6DHV7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAM10 ADAM metallopeptidase domain 10 102 O14672 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAM15 ADAM metallopeptidase domain 15 8751 Q13444 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAM17 ADAM metallopeptidase domain 17 6868 B2RNB2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAM22 ADAM metallopeptidase domain 22 53616 Q9P0K1 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ADAM23 ADAM metallopeptidase domain 23 8745 O75077 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAM28 ADAM metallopeptidase domain 28 10863 Q9UKQ2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAM9 ADAM metallopeptidase domain 9 8754 Q13443 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAMTS1 ADAM metallopeptidase with thrombospondin type 1 motif, 1 9510 Q8NE26 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ADAMTS12 ADAM metallopeptidase with thrombospondin type 1 motif, 12 81792 P58397 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAMTS3 ADAM metallopeptidase with thrombospondin type 1 motif, 3 9508 B7Z2U9 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ADAMTS8 ADAM metallopeptidase with thrombospondin type 1 motif, 8 11095 Q5FWF1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif, 9 56999 Q9P2N4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAMTSL2 ADAMTS-like 2 9719 Q86TH1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAP2 ArfGAP with dual PH domains 2 55803 Q9NPF8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADARB2 adenosine deaminase, RNA-specific, B2 105 Q9NS39 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAT1 adenosine deaminase, tRNA-specific 1 23536 Q9BUB4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADAT2 adenosine deaminase, tRNA-specific 2 134637 Q7Z6V5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADCK2 aarF domain containing kinase 2 90956 A4D1T6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADCK3 aarF domain containing kinase 3 56997 Q8NI60 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADCK4 aarF domain containing kinase 4 79934 Q96D53 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADCY3 adenylate cyclase 3 109 B3KT86 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ADCY6 adenylate cyclase 6 112 O43306 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADCY7 adenylate cyclase 7 113 P51828 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADCY9 adenylate cyclase 9 115 O60503 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADD2 adducin 2 (beta) 119 P35612 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADD3 adducin 3 (gamma) 120 Q9UEY8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADH5 alcohol dehydrogenase 5 (class III), chi polypeptide 128 P11766 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADIPOR1 adiponectin receptor 1 51094 Q96A54 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADIPOR2 adiponectin receptor 2 79602 Q86V24 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADK adenosine kinase 132 P55263 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADNP2 ADNP homeobox 2 22850 Q6IQ32 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADO 2-aminoethanethiol (cysteamine) dioxygenase 84890 B3KXN9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADORA2B adenosine A2b receptor 136 P29275 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADPGK ADP-dependent glucokinase 83440 Q9BRR6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADPRHL2 ADP-ribosylhydrolase like 2 54936 Q9NX46 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADRB1 adrenoceptor beta 1 153 P08588 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADRBK2 adrenergic, beta, receptor kinase 2 157 P35626 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADRM1 adhesion regulating molecule 1 11047 Q16186 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ADSL adenylosuccinate lyase 158 P30566 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ADSS adenylosuccinate synthase 159 P30520 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AEBP2 AE binding protein 2 121536 Q6ZN18 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AEN apoptosis enhancing nuclease 64782 Q8WTP8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AES amino-terminal enhancer of split 166 Q08117 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AFF1 AF4/FMR2 family, member 1 4299 B4DTU1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AFF2 AF4/FMR2 family, member 2 2334 P51816 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AFG3L2 AFG3 ATPase family member 3-like 2 (S. cerevisiae) 10939 Q8TA92 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AFTPH aftiphilin 54812 Q6ULP2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGAP6 ArfGAP with GTPase domain, ankyrin repeat and PH domain 6 414189 Q5VW22 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGBL3 ATP/GTP binding protein-like 3 340351 Q8NEM8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGBL4 ATP/GTP binding protein-like 4 84871 Q5VU57 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGBL5 ATP/GTP binding protein-like 5 60509 Q8NDL9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGFG1 ArfGAP with FG repeats 1 3267 P52594 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGGF1 angiogenic factor with G patch and FHA domains 1 55109 Q8N302 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGK acylglycerol kinase 55750 A4D1U5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGL amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase 178 P35573 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGPAT1 1-acylglycerol-3-phosphate O-acyltransferase 1 10554 Q99943 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGPAT2 1-acylglycerol-3-phosphate O-acyltransferase 2 10555 O15120 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGPAT5 1-acylglycerol-3-phosphate O-acyltransferase 5 55326 Q9NUQ2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGPAT6 1-acylglycerol-3-phosphate O-acyltransferase 6 137964 Q2TU73 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9 84803 Q53EU6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGPS alkylglycerone phosphate synthase 8540 O00116 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGTR1 angiotensin II receptor, type 1 185 P30556 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AGTRAP angiotensin II receptor-associated protein 57085 Q6RW13 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHCTF1 AT hook containing transcription factor 1 25909 Q8WYP5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHCY adenosylhomocysteinase 191 P23526 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHCYL1 adenosylhomocysteinase-like 1 10768 O43865 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHCYL2 adenosylhomocysteinase-like 2 23382 Q96HN2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHI1 Abelson helper integration site 1 54806 Q4FD35 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AHNAK ?AHNAK nucleoprotein 79026 Q09666 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AHNAK2 AHNAK nucleoprotein 2 113146 Q8IVF2 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AHR aryl hydrocarbon receptor 196 P35869 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHRR aryl-hydrocarbon receptor repressor 57491 A9YTQ3 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AHSA1 AHA1, activator of heat shock 90kDa protein ATPase homolog 1 (yeast) 10598 O95433 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AHSA2 AHA1, activator of heat shock 90kDa protein ATPase homolog 2 (yeast) 130872 Q719I0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIDA axin interactor, dorsalization associated 64853 Q96BJ3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIF1L allograft inflammatory factor 1-like 83543 Q9BQI0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIFM1 apoptosis-inducing factor, mitochondrion-associated, 1 9131 O95831 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIFM2 apoptosis-inducing factor, mitochondrion-associated, 2 84883 Q9BRQ8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIG1 androgen-induced 1 51390 Q9NVV5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIM1 absent in melanoma 1 202 B3KPT0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIM2 absent in melanoma 2 9447 O14862 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIMP1 aminoacyl tRNA synthetase complex-interacting multifunctional protein 1 9255 B4DNK3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIMP2 aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 7965 Q13155 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AIP aryl hydrocarbon receptor interacting protein 9049 O00170 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AK2 adenylate kinase 2 204 P54819 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AK3 adenylate kinase 3 50808 Q7Z4Y4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AK4 adenylate kinase 4 205 P27144 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP1 A kinase (PRKA) anchor protein 1 8165 B4DN86 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP10 A kinase (PRKA) anchor protein 10 11216 O43572 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP11 A kinase (PRKA) anchor protein 11 11215 Q9UKA4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP12 A kinase (PRKA) anchor protein 12 9590 Q02952 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP13 A kinase (PRKA) anchor protein 13 11214 B0AZU4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP2 A kinase (PRKA) anchor protein 2 11217 Q9Y2D5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP7 ?A kinase (PRKA) anchor protein 7 9465 O43687 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP8 A kinase (PRKA) anchor protein 8 10270 O43823 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKAP8L A kinase (PRKA) anchor protein 8-like 26993 Q9ULX6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKD1 adenylate kinase domain containing 1 221264 Q5TCS8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKIP1 A kinase (PRKA) interacting protein 1 56672 Q9NQ31 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKIRIN1 akirin 1 79647 Q9H9L7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKIRIN2 akirin 2 55122 Q53H80 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKNAD1 AKNA domain containing 1 254268 Q5T1N1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde reductase) 10327 P14550 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKR1B1 aldo-keto reductase family 1, member B1 (aldose reductase) 231 P15121 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKR1D1 aldo-keto reductase family 1, member D1 6718 P51857 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKR7A3 aldo-keto reductase family 7, member A3 (aflatoxin aldehyde reductase) 22977 O95154 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKT1 v-akt murine thymoma viral oncogene homolog 1 207 P31749 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AKT1S1 AKT1 substrate 1 (proline-rich) 84335 Q96B36 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AKT2 v-akt murine thymoma viral oncogene homolog 2 208 B4DG79 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALAD aminolevulinate dehydratase 210 P13716 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALAS1 aminolevulinate, delta-, synthase 1 211 P13196 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ALAS2 aminolevulinate, delta-, synthase 2 212 P22557 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALCAM activated leukocyte cell adhesion molecule 214 Q13740 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH18A1 aldehyde dehydrogenase 18 family, member A1 5832 P54886 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH1A2 aldehyde dehydrogenase 1 family, member A2 8854 O94788 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH1B1 aldehyde dehydrogenase 1 family, member B1 219 P30837 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 224 P51648 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH4A1 aldehyde dehydrogenase 4 family, member A1 8659 P30038 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH5A1 aldehyde dehydrogenase 5 family, member A1 7915 P51649 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 501 P49419 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 223 B9EKV4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALDOC ?aldolase C, fructose-bisphosphate 230 P09972 Y2H
Sakai Y 2011
ALG10 ALG10, alpha-1,2-glucosyltransferase 84920 Q5BKT4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG10B ALG10B, alpha-1,2-glucosyltransferase 144245 Q5I7T1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG11 ALG11, alpha-1,2-mannosyltransferase 440138 Q2TAA5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG12 ALG12, alpha-1,6-mannosyltransferase 79087 Q9BV10 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG13 ALG13, UDP-N-acetylglucosaminyltransferase subunit 79868 Q9NP73 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ALG2 ALG2, alpha-1,3/1,6-mannosyltransferase 85365 Q9H553 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG3 ALG3, alpha-1,3- mannosyltransferase 10195 Q92685 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG5 ALG5, dolichyl-phosphate beta-glucosyltransferase 29880 Q9Y673 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG6 ALG6, alpha-1,3-glucosyltransferase 29929 Q9Y672 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG8 ALG8, alpha-1,3-glucosyltransferase 79053 A6NDW6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALG9 ALG9, alpha-1,2-mannosyltransferase 79796 Q9H6U8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALKBH1 alkB, alkylation repair homolog 1 (E. coli) 8846 Q13686 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALKBH2 alkB, alkylation repair homolog 2 (E. coli) 121642 Q6NS38 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALKBH4 alkB, alkylation repair homolog 4 (E. coli) 54784 Q9NXW9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALKBH5 alkB, alkylation repair homolog 5 (E. coli) 54890 Q6P6C2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALKBH7 alkB, alkylation repair homolog 7 (E. coli) 84266 Q9BT30 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALKBH8 alkB, alkylation repair homolog 8 (E. coli) 91801 Q96BT7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALMS1 Alstrom syndrome 1 7840 Q8TCU4 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ALOX5 arachidonate 5-lipoxygenase 240 P09917 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALPK1 alpha-kinase 1 80216 Q96QP1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALPK2 alpha-kinase 2 115701 Q86TB3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALPL alkaline phosphatase, liver/bone/kidney 249 P05186 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALS2CR11 amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 11 151254 Q53TS8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALX1 ALX homeobox 1 8092 Q15699 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ALX4 ALX homeobox 4 60529 Q9H161 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMACR alpha-methylacyl-CoA racemase 23600 Q9UHK6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMBRA1 autophagy/beclin-1 regulator 1 55626 Q9C0C7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMD1 adenosylmethionine decarboxylase 1 262 P17707 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMFR autocrine motility factor receptor, E3 ubiquitin protein ligase 267 Q9UKV5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMH anti-Mullerian hormone 268 P03971 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMIGO2 adhesion molecule with Ig-like domain 2 347902 Q86SJ2 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AMIGO3 adhesion molecule with Ig-like domain 3 386724 Q86WK7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMMECR1 Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region gene 1 9949 Q9Y4X0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMMECR1L AMMECR1-like 83607 Q6DCA0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMOT angiomotin 154796 Q4VCS5 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AMOTL1 angiomotin like 1 154810 Q8IY63 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMPD2 adenosine monophosphate deaminase 2 271 B2RB47 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AMZ2 archaelysin family metallopeptidase 2 51321 Q86W34 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC10 anaphase promoting complex subunit 10 10393 Q9UM13 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC11 anaphase promoting complex subunit 11 51529 Q9NYG5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC13 anaphase promoting complex subunit 13 25847 A8K3Z6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC16 anaphase promoting complex subunit 16 119504 C5H3H2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC2 anaphase promoting complex subunit 2 29882 Q9UJX6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC4 anaphase promoting complex subunit 4 29945 Q9UJX5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC5 anaphase promoting complex subunit 5 51433 Q9UJX4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANAPC7 anaphase promoting complex subunit 7 51434 Q9UJX3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANGEL1 angel homolog 1 (Drosophila) 23357 Q9UNK9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANGEL2 angel homolog 2 (Drosophila) 90806 Q5VTE6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANGPT1 angiopoietin 1 284 Q15389 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANGPT2 angiopoietin 2 285 O15123 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKAR ankyrin and armadillo repeat containing 150709 Q70AK8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKFN1 ankyrin-repeat and fibronectin type III domain containing 1 162282 Q8N957 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKFY1 ankyrin repeat and FYVE domain containing 1 51479 Q9P2R3 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANKH ankylosis, progressive homolog (mouse) 56172 Q9HCJ1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKHD1 ankyrin repeat and KH domain containing 1 54882 Q8IWZ3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKHD1-EIF4EBP3 ANKHD1-EIF4EBP3 readthrough 404734 Q8IWZ3 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANKIB1 ankyrin repeat and IBR domain containing 1 54467 Q9P2G1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKMY1 ankyrin repeat and MYND domain containing 1 51281 Q9P2S6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRA2 ankyrin repeat, family A (RFXANK-like), 2 57763 Q9H9E1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD10 ankyrin repeat domain 10 55608 Q9NXR5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD12 ankyrin repeat domain 12 23253 Q6UB98 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD13A ankyrin repeat domain 13A 88455 Q3ZTS7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD13B ankyrin repeat domain 13B 124930 B3KS27 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD13C ankyrin repeat domain 13C 81573 Q8N6S4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD16 ankyrin repeat domain 16 54522 Q6P6B7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD18A ankyrin repeat domain 18A 253650 Q8IVF6 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANKRD18B ankyrin repeat domain 18B 441459 A2A2Z9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD26 ankyrin repeat domain 26 22852 Q9UPS8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD26P1 ankyrin repeat domain 26 pseudogene 1 124149 Q6NSI1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD27 ankyrin repeat domain 27 (VPS9 domain) 84079 Q96NW4 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANKRD28 ankyrin repeat domain 28 23243 O15084 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD32 ankyrin repeat domain 32 84250 I6L9F1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD33B ankyrin repeat domain 33B 651746 A6NCL7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD40 ankyrin repeat domain 40 91369 A8IK34 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD43 sosondowah ankyrin repeat domain family member A 134548 Q2M3V2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD44 ankyrin repeat domain 44 91526 Q8N8A2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD49 ankyrin repeat domain 49 54851 Q8WVL7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD50 ankyrin repeat domain 50 57182 Q8TB46 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD54 ankyrin repeat domain 54 129138 Q6NXT1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD57 sosondowah ankyrin repeat domain family member C 65124 Q53LP3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD6 ankyrin repeat domain 6 22881 B7Z3D2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKRD9 ankyrin repeat domain 9 122416 Q96BM1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKS1A ankyrin repeat and sterile alpha motif domain containing 1A 23294 Q05CP0 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 56899 B7Z9I9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKS6 ankyrin repeat and sterile alpha motif domain containing 6 203286 B3KXP1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANKZF1 ankyrin repeat and zinc finger domain containing 1 55139 Q9H8Y5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANLN anillin, actin binding protein 54443 Q9NQW6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANO4 anoctamin 4 121601 Q32M45 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANO5 anoctamin 5 203859 Q75V66 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANO6 anoctamin 6 196527 B3KX12 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANO8 anoctamin 8 57719 Q9HCE9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANP32A acidic (leucine-rich) nuclear phosphoprotein 32 family, member A 8125 P39687 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANP32B acidic (leucine-rich) nuclear phosphoprotein 32 family, member B 10541 Q92688 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANP32E acidic (leucine-rich) nuclear phosphoprotein 32 family, member E 81611 Q9BTT0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANUBL1 zinc finger, AN1-type domain 4 93550 Q86XD8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANXA11 annexin A11 311 P50995 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANXA2 annexin A2 302 P07355 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANXA5 annexin A5 308 P08758 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ANXA6 annexin A6 309 P08133 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ANXA7 annexin A7 310 P20073 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AOC2 amine oxidase, copper containing 2 (retina-specific) 314 O75106 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AOC3 amine oxidase, copper containing 3 (vascular adhesion protein 1) 8639 Q16853 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1AR adaptor-related protein complex 1 associated regulatory protein 55435 Q63HQ0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1G1 adaptor-related protein complex 1, gamma 1 subunit 164 O43747 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1M1 adaptor-related protein complex 1, mu 1 subunit 8907 Q59EK3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1M2 adaptor-related protein complex 1, mu 2 subunit 10053 Q9Y6Q5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1S1 adaptor-related protein complex 1, sigma 1 subunit 1174 P61966 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1S2 adaptor-related protein complex 1, sigma 2 subunit 8905 P56377 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP1S3 adaptor-related protein complex 1, sigma 3 subunit 130340 Q96PC3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP2M1 adaptor-related protein complex 2, mu 1 subunit 1173 Q96CW1 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
AP2S1 adaptor-related protein complex 2, sigma 1 subunit 1175 P53680 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP3B1 adaptor-related protein complex 3, beta 1 subunit 8546 E5RJ68 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP3M1 adaptor-related protein complex 3, mu 1 subunit 26985 Q9Y2T2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP3M2 adaptor-related protein complex 3, mu 2 subunit 10947 P53677 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP3S1 adaptor-related protein complex 3, sigma 1 subunit 1176 Q92572 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP3S2 adaptor-related protein complex 3, sigma 2 subunit 10239 P59780 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP4E1 adaptor-related protein complex 4, epsilon 1 subunit 23431 B4DM48 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AP4M1 adaptor-related protein complex 4, mu 1 subunit 9179 O00189 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APAF1 apoptotic peptidase activating factor 1 317 O14727 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APBA2 amyloid beta (A4) precursor protein-binding, family A, member 2 321 Q59G28 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
APBB2 amyloid beta (A4) precursor protein-binding, family B, member 2 323 Q92870 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APEH N-acylaminoacyl-peptide hydrolase 327 P13798 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APEX1 APEX nuclease (multifunctional DNA repair enzyme) 1 328 P27695 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APEX2 APEX nuclease (apurinic/apyrimidinic endonuclease) 2 27301 B7ZA71 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APH1A anterior pharynx defective 1 homolog A (C. elegans) 51107 Q96BI3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APH1B anterior pharynx defective 1 homolog B (C. elegans) 83464 Q8WW43 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
API5 apoptosis inhibitor 5 8539 Q9BZZ5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APIP APAF1 interacting protein 51074 Q96GX9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APLP2 amyloid beta (A4) precursor-like protein 2 334 Q06481 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
APOA1BP apolipoprotein A-I binding protein 128240 Q8NCW5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APOBEC3D apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 140564 B2CML4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APOBEC3G apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G 60489 Q9HC16 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APOLD1 apolipoprotein L domain containing 1 81575 Q96LR9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APPBP2 amyloid beta precursor protein (cytoplasmic tail) binding protein 2 10513 Q92624 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APPL1 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 26060 Q9UKG1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APPL2 adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 2 55198 Q8NEU8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APRT adenine phosphoribosyltransferase 353 P07741 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
APTX aprataxin 54840 Q7Z2E3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AQR aquarius homolog (mouse) 9716 O60306 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARAF v-raf murine sarcoma 3611 viral oncogene homolog 369 P10398 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARAP1 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 1 116985 Q96P48 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARAP3 ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3 64411 Q05CH1 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARCN1 archain 1 372 B4E1X2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARF1 ADP-ribosylation factor 1 375 Q8N6T3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARF4 ADP-ribosylation factor 4 378 P18085 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARF5 ADP-ribosylation factor 5 381 A4D0Z3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARF6 ADP-ribosylation factor 6 382 P62330 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARFGAP1 ADP-ribosylation factor GTPase activating protein 1 55738 Q8N6T3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARFGAP2 ADP-ribosylation factor GTPase activating protein 2 84364 B4DX29 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARFGAP3 ADP-ribosylation factor GTPase activating protein 3 26286 E9PB03 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARFGEF2 ADP-ribosylation factor guanine nucleotide-exchange factor 2 (brefeldin A-inhibited) 10564 Q9Y6D5 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARFIP1 ADP-ribosylation factor interacting protein 1 27236 P53367 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARFIP2 ADP-ribosylation factor interacting protein 2 23647 P53365 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARGLU1 arginine and glutamate rich 1 55082 Q9NWB6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP1 Rho GTPase activating protein 1 392 Q07960 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP10 Rho GTPase activating protein 10 79658 A1A4S6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP11A Rho GTPase activating protein 11A 9824 Q6P4F7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP12 Rho GTPase activating protein 12 94134 Q504X1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP17 Rho GTPase activating protein 17 55114 Q68EM7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP18 Rho GTPase activating protein 18 93663 Q8N392 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP19 Rho GTPase activating protein 19 84986 Q14CB8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP22 Rho GTPase activating protein 22 58504 Q7Z5H3 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARHGAP26 Rho GTPase activating protein 26 23092 Q9UNA1 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARHGAP27 Rho GTPase activating protein 27 201176 Q6ZUM4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP28 Rho GTPase activating protein 28 79822 B4DXL2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP29 Rho GTPase activating protein 29 9411 Q52LW3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP31 Rho GTPase activating protein 31 57514 Q2M1Z3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP35 Rho GTPase activating protein 35 2909 Q9NRY4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP39 Rho GTPase activating protein 39 80728 B3KS00 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP4 Rho GTPase activating protein 4 393 P98171 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP42 Rho GTPase activating protein 42 143872 A6NI28 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP44 Rho GTPase activating protein 44 9912 Q17R89 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP5 Rho GTPase activating protein 5 394 Q13017 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGAP8 Rho GTPase activating protein 8 23779 P85298 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGDIA Rho GDP dissociation inhibitor (GDI) alpha 396 P52565 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF1 Rho guanine nucleotide exchange factor (GEF) 1 9138 Q92888 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF10 Rho guanine nucleotide exchange factor (GEF) 10 9639 O15013 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF18 Rho/Rac guanine nucleotide exchange factor (GEF) 18 23370 Q6ZSZ5 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ARHGEF26 Rho guanine nucleotide exchange factor (GEF) 26 26084 B3KXG0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF3 Rho guanine nucleotide exchange factor (GEF) 3 50650 Q9NR81 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF37 Rho guanine nucleotide exchange factor (GEF) 37 389337 A1IGU5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF40 Rho guanine nucleotide exchange factor (GEF) 40 55701 Q8TER5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARHGEF5 Rho guanine nucleotide exchange factor (GEF) 5 7984 Q12774 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARID3A AT rich interactive domain 3A (BRIGHT-like) 1820 Q99856 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARID3B AT rich interactive domain 3B (BRIGHT-like) 10620 Q8IVW6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARID3C AT rich interactive domain 3C (BRIGHT-like) 138715 A6NKF2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARID4A AT rich interactive domain 4A (RBP1-like) 5926 P29374 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARID4B AT rich interactive domain 4B (RBP1-like) 51742 Q4LE39 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARID5B AT rich interactive domain 5B (MRF1-like) 84159 Q14865 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARIH1 ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 (Drosophila) 25820 Q9Y4X5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARIH2 ariadne homolog 2 (Drosophila) 10425 O95376 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL1 ADP-ribosylation factor-like 1 400 P40616 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL10 ADP-ribosylation factor-like 10 285598 Q6PCE2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL13B ADP-ribosylation factor-like 13B 200894 Q3SXY8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL15 ADP-ribosylation factor-like 15 54622 Q9NXU5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL17A ADP-ribosylation factor-like 17A 51326 Q8IVW1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL2 ADP-ribosylation factor-like 2 402 G3V184 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL2BP ADP-ribosylation factor-like 2 binding protein 23568 Q9Y2Y0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL4C ADP-ribosylation factor-like 4C 10123 P56559 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL5A ADP-ribosylation factor-like 5A 26225 Q9Y689 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL5B ADP-ribosylation factor-like 5B 221079 B0YIW9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL6IP1 ADP-ribosylation factor-like 6 interacting protein 1 23204 Q15041 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL6IP5 ADP-ribosylation-like factor 6 interacting protein 5 10550 O75915 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL6IP6 ADP-ribosylation-like factor 6 interacting protein 6 151188 B3KMZ5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL8A ADP-ribosylation factor-like 8A 127829 Q96BM9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARL8B ADP-ribosylation factor-like 8B 55207 Q9NVJ2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC1 armadillo repeat containing 1 55156 Q9NVT9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC10 armadillo repeat containing 10 83787 Q8N2F6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC4 armadillo repeat containing 4 55130 A8K906 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC5 armadillo repeat containing 5 79798 Q96C12 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC6 armadillo repeat containing 6 93436 Q6NXE6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC8 armadillo repeat containing 8 25852 B7Z637 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMC9 armadillo repeat containing 9 80210 Q7Z3E5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMCX2 armadillo repeat containing, X-linked 2 9823 Q7L311 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMCX3 armadillo repeat containing, X-linked 3 51566 Q9UH62 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARMCX4 armadillo repeat containing, X-linked 4 100131755 F8W8Y7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARNT aryl hydrocarbon receptor nuclear translocator 405 P27540 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARNTL2 aryl hydrocarbon receptor nuclear translocator-like 2 56938 Q8WYA1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPC1A actin related protein 2/3 complex, subunit 1A, 41kDa 10552 Q92747 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPC1B actin related protein 2/3 complex, subunit 1B, 41kDa 10095 A4D275 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPC2 actin related protein 2/3 complex, subunit 2, 34kDa 10109 O15144 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 10093 F6TTL5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 10092 O15511 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPC5L actin related protein 2/3 complex, subunit 5-like 81873 Q9BPX5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARPP19 cAMP-regulated phosphoprotein, 19kDa 10776 P56211 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARRB2 arrestin, beta 2 409 P32121 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARRDC1 arrestin domain containing 1 92714 Q8N5I2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARRDC2 arrestin domain containing 2 27106 Q8TBH0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARRDC3 arrestin domain containing 3 57561 Q96B67 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARRDC4 arrestin domain containing 4 91947 A8K2F6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARSB arylsulfatase B 411 P15848 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARSJ arylsulfatase family, member J 79642 Q5FYB0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ARV1 ARV1 homolog (S. cerevisiae) 64801 Q9H2C2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
AS3MT arsenic (+3 oxidation state) methyltransferase 57412 Q0VDK3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASAH1 N-acylsphingosine amidohydrolase (acid ceramidase) 1 427 A8K0B6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASAH2B N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B 653308 P0C7U1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASAP1 ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 50807 Q9ULH1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASAP2 ArfGAP with SH3 domain, ankyrin repeat and PH domain 2 8853 O43150 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASB1 ankyrin repeat and SOCS box containing 1 51665 Q9Y576 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASB11 ankyrin repeat and SOCS box containing 11 140456 E9PEN1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASB13 ankyrin repeat and SOCS box containing 13 79754 Q8WXK3 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ASB3 ankyrin repeat and SOCS box containing 3 51130 Q9Y575 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASB6 ankyrin repeat and SOCS box containing 6 140459 Q9NWX5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASB7 ankyrin repeat and SOCS box containing 7 140460 Q9H672 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASB8 ankyrin repeat and SOCS box containing 8 140461 Q9H765 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASCC1 activating signal cointegrator 1 complex subunit 1 51008 Q8N9N2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASCC2 activating signal cointegrator 1 complex subunit 2 84164 Q9H1I8 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ASCC3 activating signal cointegrator 1 complex subunit 3 10973 Q8N3C0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASF1B ASF1 anti-silencing function 1 homolog B (S. cerevisiae) 55723 Q9NVP2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASH2L ash2 (absent, small, or homeotic)-like (Drosophila) 9070 Q9UBL3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASL argininosuccinate lyase 435 P04424 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASNS asparagine synthetase (glutamine-hydrolyzing) 440 P08243 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASNSD1 asparagine synthetase domain containing 1 54529 Q9NWL6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASPH aspartate beta-hydroxylase 444 B4E2K4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASPHD1 aspartate beta-hydroxylase domain containing 1 253982 Q5U4P2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 259266 B3KWI2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASPSCR1 alveolar soft part sarcoma chromosome region, candidate 1 79058 Q9BZE9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASRGL1 asparaginase like 1 80150 Q7L266 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASTE1 asteroid homolog 1 (Drosophila) 28990 Q2TB18 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASTN2 astrotactin 2 23245 O75129 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASXL1 additional sex combs like 1 (Drosophila) 171023 Q498B9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASXL2 additional sex combs like 2 (Drosophila) 55252 Q76L83 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ASXL3 additional sex combs like 3 (Drosophila) 80816 Q9C0F0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATAD1 ATPase family, AAA domain containing 1 84896 Q8NBU5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATAD2 ATPase family, AAA domain containing 2 29028 Q6PL18 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATAD2B ATPase family, AAA domain containing 2B 54454 Q9ULI0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATAD3A ATPase family, AAA domain containing 3A 55210 Q9NVI7 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATAD3B ATPase family, AAA domain containing 3B 83858 Q5T9A4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATAD5 ATPase family, AAA domain containing 5 79915 Q96QE3 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATE1 arginyltransferase 1 11101 O95260 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATF1 activating transcription factor 1 466 P18846 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATF2 activating transcription factor 2 1386 P15336 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATF3 activating transcription factor 3 467 P18847 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATF4 activating transcription factor 4 (tax-responsive enhancer element B67) 468 P18848 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATF6 activating transcription factor 6 22926 A8K383 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATF6B activating transcription factor 6 beta 1388 Q99941 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG10 autophagy related 10 83734 Q9H0Y0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG12 autophagy related 12 9140 O94817 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG13 ATG13 autophagy related 13 homolog (S. cerevisiae) 9776 O75143 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG14 autophagy related 14 22863 Q6ZNE5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG16L1 autophagy related 16-like 1 (S. cerevisiae) 55054 Q53SV2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG4B autophagy related 4B, cysteine peptidase 23192 B3KVU2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG4C autophagy related 4C, cysteine peptidase 84938 Q96DT6 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG4D autophagy related 4D, cysteine peptidase 84971 Q86TL0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG5 autophagy related 5 9474 A9UGY9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATG7 autophagy related 7 10533 O95352 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATIC 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase 471 P31939 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATL2 atlastin GTPase 2 64225 Q8NHH9 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATL3 atlastin GTPase 3 25923 Q6DD88 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATM ?ataxia telangiectasia mutated 472 Q13315 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ATP11A ATPase, class VI, type 11A 23250 P98196 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP11B ATPase, class VI, type 11B 23200 B4DKX1 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP11C ATPase, class VI, type 11C 286410 Q8NB49 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP13A3 ATPase type 13A3 79572 Q9H7F0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP1B3 ATPase, Na+/K+ transporting, beta 3 polypeptide 483 P54709 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP2A1 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 487 O14983 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP2B1 ATPase, Ca++ transporting, plasma membrane 1 490 P20020 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 27032 P98194 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 509 P36542 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 513 P30049 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5F1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1 515 P24539 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 (subunit 9) 516 P05496 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5G2 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) 517 Q06055 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5G3 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C3 (subunit 9) 518 P48201 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5I ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E 521 P56385 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5J ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F6 522 P18859 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 539 P48047 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5S ATP synthase, H+ transporting, mitochondrial Fo complex, subunit s (factor B) 27109 Q99766 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP5SL ATP5S-like 55101 B4DXE8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 1 537 Q15904 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6AP1L ATPase, H+ transporting, lysosomal accessory protein 1-like 92270 Q52LC2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2 23545 Q9Y487 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 533 D3DPY5 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V0C ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c 527 P27449 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 8992 O15342 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V0E2 ATPase, H+ transporting V0 subunit e2 155066 E9PAS2 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 523 P38606 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 528 P21283 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1D ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D 51382 Q9Y5K8 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1E1 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 529 P36543 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1F ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F 9296 Q16864 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 9550 O75348 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit H 51606 Q9UI12 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP7B ATPase, Cu++ transporting, beta polypeptide 540 B7ZLR4 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP8A1 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 10396 Q9Y2Q0 PAR-CLIP (HEK293 cells)
Ascano M Jr 2012
ATP8A2 ATPase, aminophospholipid transporter, class I, type 8A, member 2 51761 Q6ZSP3 PAR-CLIP (HEK293 cells)
RNA-IP (HEK293 cells)
Ascano M Jr 2012
ATP8B1 ATPase, aminophospholipid transporter, class I, type 8B, member 1 5205 O43520